Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442
Summary of Product Characteristics last updated on the eMC: 26/06/2009
SPC FAMVIR 750 mg Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 26/06/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.2 - Pharmacokinetic Properties
Date of revision of text on the SPC:   12-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

The Famvir SmPC has been separated into 4 different SmPCs, one for each strength. 
There has been a correction to dosing in Section 4.2.
There has been an update to the patient population information in section 5.2: additional information on subjects with renal impairment, hepatic impairment, the elderly and gender.
Updated on 19/09/2001 and displayed until 26/06/2009
Reasons for adding or updating:
  • Correction of spelling/typing errors
  • SPC Retired pending re-submission

Active Ingredients/Generics

 
   famciclovir


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk